The Commission has authorised the Nuvaxovid XBB.1.5-adapted COVID-19 vaccine, developed by Novavax. This is another important step in the fight against the disease. It is the first protein-based adapted vaccine authorised for this autumn and winter season. The European Medicines Agency (EMA) carried out an in-depth evaluation of the vaccine. Following this evaluation, the Commission […]